Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-010: nemtabrutinib + venetoclax versus venetoclax + rituximab in relapsed/refractory CLL/SLL
MOH_2023-04-23_012529Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Nemtabrutinib + venetoclax with Venetoclax + rituximab (2 arms). Started Mar 2023; status: recruiting.
02
Drugs
nemtabrutinibvenetoclaxrituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2023-04-23_012529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-23_012529.